April 2005
Crompton, Great Lakes Merge

In a $1.8 billion (Euro 1.36 billion) stock swap deal, Crompton Corporation and Great Lakes will merge to form the third largest publicly traded U.S. specialty chemicals company. Crompton will own 51 percent of the new organization, which it says will have a combined revenue of over $4.1 billion. Current Crompton chairman, president and CEO Robert Wood will have the same responsibilities for the new company. Annual cost savings of $90 - $100 million are anticipated by Crompton beginning in 2006.

 

Famous Quotes of the Month
- Don't worry about people stealing an idea. If it's original, you will have to ram it down their throats. (Howard Aiken)

- The best way to predict the future is to invent it. (Alan Kay)

- What happens is not as important as how you react to what happens. (Thaddeus Golas)

- I am a great believer in luck, and I find that the harder I work, the more I find I have of it. (Thomas Jefferson)

- Conditions are never just right. People who delay action until all factors are favorable do nothing. (William Feather)




Why is the Home Plate in Baseball Such a Weird Shape?
Baseball has been around more than 200 years. The earliest references to the game being played are from Pittsfield, Massachusetts in 1791. For more than 100 years, home plate was square like all the other bases. But in the year 1900, the current pentagonal plate was introduced to help umpires in calling balls and strikes. Umpires found it easier to spot the location of the ball when the plate was elongated. If you ask most players, they will tell you that it hasn't helped much.




C6 Solutions Exits Fine Chemicals Business
C6 Solutions placed its manufacturing plant and equipment up for sale and plans to phase out operations over the summer, citing the weak dollar, competition from Asia, and excess capacity in customer markets. Approximately 300 people are employed by the company.



Restructuring Appears Effective for Bayer

Bayer is projecting higher margins and increasing sales and earnings following the major restructuring of the company that included the spin-off Lanxess, which includes its former chemicals and some polymers operations Bayer has suffered financial difficulties since 2001 when it had to withdraw its Baycol/Lipobay cholesterol-lowering drug. In the health care market, Bayer plans on becoming the leading provider of consumer health products, and a modest player in pharmaceuticals. The company claims it has overtaken the top position in agrochemicals form Syngenta and hopes to remain the leader in that industry. Bayer plans to build its materials science business through acquisitions and alliances.



Sasol Faces Creosote Price Discrimination Charge
The South African Competition Tribunal charged Sasol with unlawful price discrimination in the pricing of Creosote. The company was found guilty of failing to give similar price discounts to a small, privately owned business as it did to bulk producers. Sasol, which had no comment on the ruling, has the right to appeal.




New Sasol CEO Takes Helm In Difficult Times

Executive Director Pat Davies has been appointed CEO of Sasol effective July 1, 2005, replacing Pieter Cox, who will succeed Paul Kruger as chairman of the board beginning January 1, 2006. Sasol also appointed Trevor Munday to the new position of deputy chief executive. His job will be to provide Davies with support in the management of the company's significantly expanded global interests.

Davies will immediately manage several major projects, including the commissioning of Sasol's polymer facilities in Iran, startup of gas-to-liquids (GTL) plants in Qatar and Nigeria, and completion of feasibility studies for a coal-to-liquids (CTL) facility in China.

In South Africa, Davies must address Sasol's poor safety record and rebuild its relationship with the government and trade union. It also must secure a partner for its chemicals operations that meets the requirements of the black economic empowerment (BEE) legislation. The company has also been rebuked for not having enough black managers. Sasol has responded by noting that it has appointed former high-ranking officials from the ruling African National Congress (ANC) government as senior advisers on BEE policy.

Recently there has been speculation that a U.S. petrochemicals company may make a bid for Sasol. According to the company it is only a rumor. The company has also had to respond to suggestions that it may sell its Condea olefins, surfactants and solvents (O&S) operations in Germany due to its poor performance. As a key shareholder, the South African government said it will oppose any foreign bid for Sasol.




2004 Was Positive Year for European Chemicals Industry
According to Cefic, the European Chemical Industry Council, excluding pharmaceuticals, European Union (EU) chemicals production increased 2.9 percent in 2004, the largest gain in four years. Strongest growing segments included petrochemicals, plastics, and fine and specialty chemicals. Modest increases were seen for basic inorganics, while consumer chemicals and man-made fibers experienced only minor expansion. The growth rate of pharmaceuticals decreased greatly as compared to recent years. Cefic expects 2005 to be a strong year as well, although growth rates may be slightly dampened.



Russian Chemical Industry Attractive to Foreign Investment
In 2004, Russian petrochemicals output rose 7 percent by volume as compared to 2003, while export revenues increased and domestically produced chemicals began to replace previously imported products. In 2003, foreign investments totaled approximately $500 million, with companies such as Procter & Gamble and Henkel investing in local production through acquisitions or construction of new facilities. In 2005, Russia's lower house of parliament, the State Duma, is expected to approve a five-year plan to improve growth of the chemicals industry in the country. Compared to the Middle East, Russia may be an attractive alternative for business operations.

The challenges are significant, though, for those foreign investors considering the opportunities in Russia. Much of the chemical industry infrastructure is old and in poor condition following many years without any capital investment. Some Russian businesses are buying petrochemical companies and improving the assets so they can competitively export the materials they are producing. A growing domestic market and a sense of political stability are resulting in more of this type of activity. The need for expansion and modernization of the logistics infrastructure is also great. Overcoming the large distances between feedstock sources, processing plants, and consumer markets is a significant challenge. Cultural differences may also be a factor.



Tight Chemical Markets Attractive to Analysts
Many analysts believe that the tight supply and demand balances in many chemical sectors bode well for investors. Many are assigning "buy" ratings to chemical companies as well as raising profit projections for these companies. "Buy" ratings have been listed for Westlake Chemical, PPG Industries, Georgia Gulf, and Albemarle. Most of these companies are also expected to have higher earnings per share (EPS) than originally estimated by the analysts.



U.S. Chemicals Slow Temporarily, But Overall Growth Predicted for 2005
Prices of chemical stocks have fallen recently in response to weaker demand and lower margins, a trend also experienced in other cyclical industries such as steel, paper, and construction. Despite these declines, most analysts expect the market to continue its overall upward movement for the remainder of the year, with increasing demand and rising prices. According to the Federal Reserve Board, domestic demand for chemicals in the U.S. remains "extremely strong." The Fed indicated that "significant capital expansion" on the Gulf Coast will be required to meet the growing demand.




Codexis Makes European Acquisition
With the acquisition of Juelich Fine Chemicals, Codexis gained its first facility in Europe. Operating as a wholly owned subsidiary of Codexis, Jeulich will add its catalog of specialty enzymes and chiral intermediates in addition to its custom services to the company's portfolio as well as provide a channel of distribution for Codexis' proprietary enzymes. The purchase was made for an undisclosed amount.



ISP Expands Butanediol Business Through Acquisition

BP Amoco Chemical Company sold its 1,4-butanediol (BDO) operations at its Lima, OH plant to a subsidiary of International Specialty Products Inc. (ISP) for an undisclosed amount. The acquisition strengthens ISP's position in the BDO market, ensuring its ability to meet increasing demands for the compound.



More Acquisitions for SAFC

Sigma Aldrich Fine Chemicals (SAFC) acquired Degussa's Proligo Group and the JRH Biosciences division of CSL Limited. The Proligo Group was purchased for an undisclosed amount and adds a line of nucleic acids and oligonucleotides to SAFC's portfolio. The JRH Biosciences transaction was completed at a cost of $370 million (Euro 280 million). The acquisition will enable SAFC to better meet demands in the biopharma market for cell culture and sera products.



Quaker Chemical Buys Out Brazilian Joint Venture

Quaker Chemical acquired the 40 percent interest of partner Siderquimica in the two companies' joint venture that provides process chemicals to the Brazilian steel industry. Quaker bought out its partner so that it could bring the business in line with its global strategic operations.



Strong Potential for Growth in Japanese Outsourcing
In April, the Pharmaceutical Affairs Law (PAL) will make it possible for Japanese-based pharmaceutical firms to outsource all steps in the drug making process. Increasing demand for custom manufacturing services of U.S. and European providers is expected from these companies as a result of the new legislation. Drug firms will be required to separate their marketing and manufacturing activities. Responsibility for production will be given to a qualified individual known as the marketing authorization holder (MAH), who will oversee quality control, inspections, and outsourcing. The PAL legislation also brings Japanese rules more closely in alignment with the U.S. FDA regulations, making it easier for Japanese pharmaceutical companies to export their products.




Consolidation Expected Among Leading Generics Firms
The demand for health care cost containment is resulting in the creation of legislation and policies supporting generic drug manufacturers. Currently the top generic firms are global players themselves and are often outperforming their big pharma counterparts. Further consolidation among both global and regional generic producers is expected, however, as competition from India and China increases. China currently competes on older pharmaceutical compounds, but many producers are slowly replacing older facilities with new plants that will be capable of producing high quality, low cost versions of the latest drugs to come off patent. A recent example of consolidation is the acquisition by Novartis' generic business Sandoz of both Eon Labs Inc. and Hexal AG for $8.5 billion earlier in 2005.



Lackluster Performance for Large Pharma Companies
The delay in many new chemical entity approvals, strong generics competition, increased demand for over-the-counter products, safety-related issues, and pricing pressures from the government have all negatively impacted growth in the pharmaceuticals sector. In addition to these trends, the drug companies must also contend with composition of matter patent challenges that may hamper their ability of to defend against future generic competition. Pricing pressures from the government are only expected to increase, with investigations into pharma industry pricing practices and the introduction of the Medicare drug benefit program in 2006.

On the positive side, the repatriation provision of the American Jobs Creations Act will make it possible for drug companies to bring foreign earnings back into the U.S. at a much lower tax rate. Analysts estimate that amount could be as much as $90m billion for just the top 6 drug companies. Additional consolidation and licensing arrangements are also expected. Recent tort reform may also reduce costs for pharma companies, especially those hit with large liability cases such as Merck (due to Vioxx).



Solvay Agrees to Acquire Fournier Pharma
Solvay announced that it has reached an agreement to purchase Fournier Pharma for $1.7 billion (Euro 1.3 billion) in cash. The deal is expected to close in the summer of 2005 following receipt of regulatory approvals. The acquisition will increase Solvay's pharma sales by over one third and add significantly to the company's pipeline.




China Consolidates Agrochemicals Sector
With a goal of creating a major agrochemical firm that can compete in the international marketplace, China National Chemical Corp. (CNCC) plans to acquire a number of smaller agrochemical producers and R&D sites with funding from the China Development Bank (CDB). Approximately 2000 different agrochemical companies in China account for only 5% of the global agchem market, according to CNCC. Both CNCC, which was formed in 2004 through the merger of China National Bluestar Corp. and China Haohua Chemical Industrial Corp., and CDB, are state owned entities.




Serono Invests in Biologics and India
Serono plans to increase its biologics capacity at Corsier-sur-Vevey, Switzerland by eight times, investing a total of $275 million in 12 new mammalian cell fermentation process reactors. A further $50 - $60 million will be invested in additional capacity at Martillac, France. By 2010 the company expects to have total biologics capacity of 220,000 - 230,000 liters. Serono also announced plans to begin sourcing intermediates from various Indian companies in 2005.



Shortage of Capacity Anticipated for Biopharmaceuticals
Despite a current excess of capacity, demand for biomanufacturing is expected to exceed supply by 2008 or 2009 as the number of biopharmaceutical drugs to reach the market continues to increase. According to HighTech Business Decisions, more than 100 biologics have been approved since 1997, and of those, at least seven have achieved sales of more than $1 billion each. The company estimates that 20-30 percent of biomanufacturing is outsourced, but expects this amount to grow as pharma companies look to partnerships with custom manufacturers to provide needed additional capacity.




China Predicted to be Dominant Player in Vinyls Market
According to leading analysts, China will account for 35% of the global trade in vinyls products by 2009. Overall, China will become the largest producer, exporter, and importer of vinyls products by that time. Vinyls products include Vinyl chloride monomer (VCM), Polyvinyl chloride (PVC), and Ethylene dichloride (EDC). Of the three, China is expected to rely heavily on imports of VCM and EDC.



Innovene Begins Operating April 1, 2005

Beginning April 4th, the olefins and derivatives (O&D) business of BP began operating independently under the name Innovene. BP plans to divest the $15 billion business before the end of 2005, possibly through an initial public offering. Innovene has been separated from BP in order to increase flexibility in its operations, decision making, and customer service. Ralph Alexander will serve as CEO, while the former business unit leader for Olefins Americas at BP Janet Roemer will take the chief of staff position.

Corporate headquarters will be located in Chicago, while North American operations will originate in Houston. Asia-Pacific headquarters will be in Shanghai, China. Innovene will assume BP's 50 percent share of Secco Petrochemical Co (Secco), which began operation of a 900,000 tonne/year cracker in Caojing, Shanghai in March, 2005. According to Innovene officials, the company will be looking at further opportunities in China and the Middle East.



MDI Market Strong
Tight supply in combination with strong demand has enabled U.S. suppliers of Methylene diphenyl diisocyanate (MDI) to push through price increases. The shortage of capacity is expected to continue due to a lack of reinvestment in MDI production facilities.



Strong Titanium Dioxide Market Continues in 2005
Continued strong demand in all major market segments for Titanium dioxide including paper, plastics and coatings will contribute to a very good year for this chemical. Despite further price increases, high growth is expected to continue as well, with global growth estimated to be 3-4 percent in 2005. Growth in Asia will remain strongest. Despite the tight supply, some producers took capacity off line in 2004 because they were not earning their cost of capital. As a result, supply will be even tighter in 2005.




Givaudan Expects Challenging Times Ahead for Flavors and Fragrances
Leading flavor and fragrance manufacturers have faced declines in sales growth for several continuous quarters due to commoditization and increased competition Givaudan has exited commodity markets such as food ingredients and is focused on building a stronger specialty product mix to ensure a competitive and profitable position. The company has launched several development centers around the world and is also targeting the growing market in China.




Increased Supplies from Middle East Will Expand European Plastics Distribution
Growth of 4-5 percent in the European plastics distribution market will be largely driven by the need for Middle Eastern plastics producers to expand their sales in Europe. Distributors have found that forming strong partnerships with producers, combined with excellent customer service and supply chain management capabilities, is necessary for success in a difficult market. Some growth will also result from expansion in central and Eastern Europe.



Vietnamese Plastics Industry Must Prepare for Growth
Plastics demand in Vietnam is expect to grow at nearly 30 percent for the next few years. The domestic plastics industry in Vietnam, however, must overcome several challenges before it can take advantage of the opportunity presented by such a growth rate. The lack of an established petrochemicals industry is a major hurdle. Currently Vietnam imports nearly 95 percent of its polymer needs, and will continue to do so over the next 5-10 years, resulting in increasing margin squeezes for downstream plastics producers as the prices of these raw materials continue to rise. Reduced profits will make it difficult for plastics processors to invest in the latest technology and equipment. The processing industry is highly fragmented and largely comprised of small and family-owned businesses that either do not care to invest in technology or lack the funds to do so. The Vietnamese government has either removed or significantly reduced import duties on resins such as Polyethylene, Polypropylene, and Polyvinyl chloride. However, many producers say the government has not done enough.

Polyethylene, Polystyrene, and Polypropylene plants are planned by the Vietnam Saigon Plastics Association (VSPA) and Vietnam National Chemical Corp (VinaChem). The Ministry of Industry in Vietnam expects it will take 5-15 years to develop a petrochemicals base in the country. In the mean time, many of the small and medium sized plastic processors in Vietnam are focused on offering low cost, small volume, customized and specialty plastics products for the European market. Some are gaining access to wide distribution networks by partnering with international companies. In 2004, the government closed state-owned Vinaplast Corp. and plans to privatize many of the remaining state-owned plastics enterprises.




European R&D Could Shift to China in Response to Reach Regulations

The European chemical industry council (Cefic) believes that European chemical companies may move their R&D operations to China if the European Union's registration, evaluation and authorization of chemicals (Reach) policy goes into affect in its present form. According to Rene Van Sloten, director for international trade and competitiveness at Cefic, the Reach regulations could impact Europe's position as the major chemical producer in the world. In order to be competitive, Europe must provide companies with a business climate that fosters innovation and technology development, combined with increased economic performance and flexibility.



International Chemical Companies Face Regulatory Challenges in China
Confusing regulations regarding imports, intellectual property, and environmental protection make it difficult for chemical companies to conduct business in China. The regulatory exemption for low volume imports is only occasionally implemented. Vague environmental regulations results in different interpretations of environmental regulations in different regions and can cause conflicts between provincial agencies and the central government. Lack of certified testing facilities makes it difficult to comply with new testing requirements. Lengthy review times (sometimes close to one year) and unspecified fees for chemical product applications also pose a challenge for chemical manufacturers.



Pirate Attacks in the Straits of Malacca
Indonesian pirates have increased their activity in Malaysian and international waters in the Straits of Malacca recently. At least three attacks were reported in March. In the past, pirates were restricting their activities to Indonesian waters. They typically kidnap the crew with the expectation of receiving a ransom from the ship owners.



US Chemical Companies Should Prepare for Implementation of European Reach Regulations
The European Reach (registration, evaluation and authorization of chemicals) regulation will undergo a detailed review at the meetings of the Competitiveness Council and the Environment Council in June, with a common position expected to be available by the end of 2005. The U.S. chemical industry has been invited to participate in the development of the regulation, particularly relating to the registration process, confidentiality issues, enforcement powers, allowances for smaller businesses, prioritization of testing for chemicals, and testing guidelines for end product imports.

The American Chemistry Council's president Tom Reilly said that he expects the Reach regulation will result in the de-industrialization of Europe. He also warned that Reach "will work to the detriment of the European economy and the future of chemistry." Reilly called the Reach program an over reaction by European regulators to the perceived risks of chemicals, and suggested that policy makers are choosing to attack chemicals rather than take the unpopular approach of addressing the problems associated with risky behaviors.

Although implementation of Reach will most likely not begin until 2007, U.S. companies that do business in Europe should think about preparing for the regulation. Companies that are not able to meet Reach requirements will not be competitive in the European market. Evaluation of product lines to identify those substances that might be affected by Reach directly or indirectly (through regulation of feedstocks) is also important. U.S. firms should also look for opportunities to form consortia with other producers to share testing costs.




In This Issue

Featured Article
Famous Quotes
Imponderables
Companies
Personnel
Business/Finance
Fine & Specialty Chemicals
Pharma
Agrochemicals
Biotech
Commodity Chemicals
Flavor & Fragrance
Plastics
General







 

Corporate HQ:
9101 LBJ Frwy.
   Suite 310
Dallas, TX 75243 USA
Tel: (214) 349-6200
Fax: (214) 349-6286
9101 LBJ Frwy., Suite 310 | Dallas, TX 75243